Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology. Show more

Location: | Website: sigilon.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$22.47

Open

$22.47

Volume

N/A

Day Range

$22.47 - $22.47

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

8.69%

Institutional Own.

54.33%

Qtr Updated

09/30/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SIG-005 Details MPS-1 (Mucopolysaccharidosis Type 1)	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SIG-001 Details Hemophilia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.